Does Medicare Cover Wegovy in 2026? Everything You Need to Know

If you are a Medicare beneficiary who has been wondering whether Medicare covers Wegovy, the answer has changed dramatically in 2026. Specifically, a new federal program called the Medicare GLP-1 Bridge is making Wegovy available to eligible Medicare beneficiaries at a significantly reduced cost starting July 1, 2026. At Craig Smith Insurance Group, we help clients across Queens, Long Island, the Bronx, Westchester, and New Jersey understand their Medicare benefits. Therefore, in this guide, we will explain exactly what Medicare covers for Wegovy in 2026. We will also discuss who qualifies and what you need to do to access this coverage.

What Is Wegovy?

First, it is helpful to understand what Wegovy is and why so many Medicare beneficiaries are asking about it. Wegovy is an FDA-approved prescription medication containing semaglutide, the same active ingredient found in Ozempic. However, while Ozempic is approved specifically for Type 2 diabetes, Wegovy is approved for chronic weight management in adults with obesity. It also reduces the risk of serious cardiovascular events in adults with established heart disease who are overweight or obese.

Furthermore, Wegovy has attracted enormous attention because of its effectiveness. Clinical studies have shown that people taking Wegovy can lose a significant percentage of their body weight. This makes Wegovy one of the most effective weight loss medications currently available. As a result, demand for Wegovy among Medicare beneficiaries has been extremely high. Until recently, coverage was very limited.

Did Medicare Previously Cover Wegovy?

Until 2026, Medicare’s coverage of Wegovy was extremely limited. Specifically, federal law historically prohibited Medicare Part D plans from covering medications used exclusively for weight loss. As a result, most Medicare beneficiaries had to pay the full out-of-pocket cost of Wegovy. This typically ranges from $900 to $1,300 per month without insurance. This price made it unaffordable for most seniors on fixed incomes.

However, there was one important exception. Medicare Part D could cover Wegovy when it was prescribed specifically to reduce the risk of cardiovascular death, heart attack, or stroke in adults with established heart disease who are overweight or obese. Therefore, some beneficiaries with qualifying cardiovascular conditions were able to access Wegovy through their Part D plan before 2026.

The Medicare GLP-1 Bridge — A Game Changer for 2026

The biggest Medicare news of 2026 for beneficiaries struggling with obesity is the launch of the Medicare GLP-1 Bridge program. Specifically, beginning July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) is making select GLP-1 medications, including Wegovy, available to eligible Medicare beneficiaries at a $50 monthly copay through this new demonstration program.

This is a dramatic change from the previous situation, where most Medicare beneficiaries had no coverage for Wegovy at all. Consequently, the Medicare GLP-1 Bridge represents one of the most significant expansions of Medicare drug coverage in recent years.

Which Medications Are Covered Under the Medicare GLP-1 Bridge?

The Medicare GLP-1 Bridge covers the following FDA-approved weight loss medications:

• Wegovy (semaglutide) — available in both injection and oral tablet form
• Zepbound (tirzepatide) — KwikPen formulation only
• Foundayo — all formulations

It is important to note that Ozempic and Mounjaro are not covered under the GLP-1 Bridge program for weight loss. However, those medications continue to be covered by Medicare Part D when prescribed for Type 2 diabetes. Furthermore, compounded versions of semaglutide or tirzepatide are not covered under this program; only FDA-approved brand-name medications qualify.

How Much Does Wegovy Cost Under the Medicare GLP-1 Bridge?

Under the Medicare GLP-1 Bridge, eligible beneficiaries can access Wegovy for a $50 monthly copay. This is a remarkable reduction from the standard retail price of $900 to $1,300 per month. As a result, the GLP-1 Bridge makes Wegovy accessible to a much broader population of Medicare beneficiaries who previously could not afford it.

How Long Does the Medicare GLP-1 Bridge Last?

The Medicare GLP-1 Bridge runs from July 1, 2026, through December 31, 2027. After that, a longer-term program called the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) is expected to take over. This program will provide continued Medicare coverage of GLP-1 medications for obesity management. Therefore, beneficiaries who begin Wegovy under the GLP-1 Bridge should plan ahead for what happens when the program transitions to the BALANCE Model.

Who Is Eligible for the Medicare GLP-1 Bridge?

Not every Medicare beneficiary qualifies for the GLP-1 Bridge program. Specifically, eligibility is based on the following criteria:

• Medicare enrollment — you must be enrolled in Medicare Part D or a Medicare Advantage plan with drug coverage
• Obesity diagnosis — you must have a qualifying obesity diagnosis from your healthcare provider
• BMI requirements — you must meet specific BMI thresholds as determined by CMS
• Prescription from a qualified provider — your doctor must prescribe one of the covered GLP-1 medications for weight management

Additionally, your Medicare Part D plan or Medicare Advantage plan must participate in the GLP-1 Bridge program. Therefore, it is important to confirm with your plan that they are participating before assuming you will have access to the $50 copay.

Does Medicare Cover Wegovy for Cardiovascular Conditions?

Yes — separate from the GLP-1 Bridge program, Medicare Part D may also cover Wegovy for beneficiaries with established cardiovascular disease. Specifically, Wegovy is FDA-approved to reduce the risk of cardiovascular death, heart attack, or stroke in adults with existing heart disease who are overweight or obese. As a result, many Part D plans cover Wegovy for this cardiovascular indication even outside of the GLP-1 Bridge program.

However, coverage for the cardiovascular indication depends on your specific Part D plan’s formulary. Furthermore, prior authorization is typically required. This means your doctor will need to submit documentation confirming your cardiovascular diagnosis and the medical necessity of Wegovy. Therefore, if you have heart disease and are overweight or obese, ask your doctor whether Wegovy may be appropriate for you. Also, inquire whether your Part D plan covers it.

What to Do If Your Medicare Plan Does Not Cover Wegovy

If your current Medicare plan does not cover Wegovy or is not participating in the GLP-1 Bridge, there are several steps you can take:

1. Contact your plan directly — call your Part D plan or Medicare Advantage plan to confirm whether they are participating in the GLP-1 Bridge and what the process is for accessing coverage
2. Review your formulary — check whether Wegovy is listed on your plan’s drug formulary and under what conditions it is covered
3. Request prior authorization — work with your doctor to submit a prior authorization request if your plan requires one
4. Consider switching plans during open enrollment — if your current plan does not participate in the GLP-1 Bridge or BALANCE Model, you may want to switch to a participating plan during the Annual Enrollment Period (October 15 to December 7)
5. Appeal a denial — if your request for coverage is denied, you have the right to appeal the decision through your plan’s appeals process

What Is the BALANCE Model — and What Comes After the GLP-1 Bridge?

The GLP-1 Bridge is a short-term demonstration program that runs through the end of 2027. After that, CMS plans to transition to the BALANCE Model, which is designed to provide longer-term Medicare coverage of GLP-1 medications for obesity management. Furthermore, in 2027, Medicare-negotiated prices for semaglutide are set to take effect. This change should reduce costs further for beneficiaries.

Therefore, if you begin Wegovy under the GLP-1 Bridge, it is important to plan for the transition to the BALANCE Model. Specifically, during Medicare open enrollment this fall, check whether your Part D plan will participate in the BALANCE Model for 2027. If not, consider switching to a plan that does. In this way, you can maintain your GLP-1 coverage without a gap.

Frequently Asked Questions — Medicare and Wegovy 2026

Does Medicare cover Wegovy in 2026?

Yes — starting July 1, 2026, eligible Medicare beneficiaries can access Wegovy through the Medicare GLP-1 Bridge program for a $50 monthly copay. Additionally, Medicare Part D may cover Wegovy for beneficiaries with established cardiovascular disease, depending on their specific plan.

How much does Wegovy cost with Medicare in 2026?

Under the Medicare GLP-1 Bridge program, eligible beneficiaries pay a $50 monthly copay for Wegovy. Without this program, the retail cost of Wegovy typically ranges from $900 to $1,300 per month. Therefore, the GLP-1 Bridge is a significant financial benefit for qualifying Medicare beneficiaries.

Does Medicare Advantage cover Wegovy?

Yes — if your Medicare Advantage plan includes Part D drug coverage and is participating in the GLP-1 Bridge, you can access Wegovy for the $50 monthly copay. However, coverage varies by plan. It is important to confirm participation with your specific Medicare Advantage plan.

Is Ozempic covered by Medicare for weight loss?

No — Ozempic is not covered by Medicare for weight loss under the GLP-1 Bridge program. Ozempic is covered by Medicare Part D when prescribed for Type 2 diabetes. The GLP-1 Bridge only covers Wegovy, Zepbound, and Foundayo for weight loss.

When does the Medicare GLP-1 Bridge end?

The Medicare GLP-1 Bridge runs from July 1, 2026, through December 31, 2027. After that, CMS plans to transition to the longer-term BALANCE Model program. Therefore, beneficiaries should monitor updates from CMS and their Medicare plan about the transition.

Have Questions About Your Medicare Drug Coverage?

Navigating Medicare drug coverage — especially with new programs like the GLP-1 Bridge being introduced can be complex and confusing. Fortunately, as an independent Medicare broker serving Queens, Long Island, the Bronx, Westchester, Rockland County, and New Jersey, I help clients understand their Medicare drug coverage options every day. I offer this service at no cost to them.

Whether you have questions about Wegovy coverage, want to review your current Part D plan, or need help switching to a plan that participates in the GLP-1 Bridge, I am here to help. Furthermore, with the Annual Enrollment Period approaching this fall, now is a great time to review your Medicare coverage. This will help ensure you have the best plan for your needs in 2027.

📞 Call (917) 740-1895
✉️ craigsmith@csmedicare.net
🌐 csmithinsurancegroup.com
🕐 Monday–Friday 9 AM–8 PM | Saturday 10 AM–1 PM

We are not connected with or endorsed by the United States Government or the federal Medicare program. We do not offer every plan available in your area. Please contact Medicare.gov or 1-800-MEDICARE for information on all your options.